[G18-06] Brentuximab vedotin (cutaneous T-cell lymphoma) - Addendum to Commission G18-01
Last updated 05.07.2018
Project no.:
G18-06
Commission:
Commission awarded on 23.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| G18-01 | Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-07-05 A G-BA decision was published.